Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126493511 | 12649351 | 1 | I | 20160616 | 20160803 | 20160812 | 20160812 | EXP | GB-MHRA-EYC 00143118 | GB-MYLANLABS-2016M1032500 | MYLAN | 0.00 | Y | 0.00000 | 20160812 | CN | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126493511 | 12649351 | 1 | PS | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 10 MG, QD | 20 | MG | Y | U | 91226 | 10 | MG | QD | |||
126493511 | 12649351 | 2 | C | INSULIN | INSULIN NOS | 1 | UNK | U | 0 | ||||||||||
126493511 | 12649351 | 3 | C | ATENOLOL. | ATENOLOL | 1 | 25 MG, UNK | U | 0 | 25 | MG | ||||||||
126493511 | 12649351 | 4 | C | DOXAZOSIN | DOXAZOSINDOXAZOSIN MESYLATE | 1 | 2 MG, UNK | U | 0 | 2 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126493511 | 12649351 | 1 | Blood cholesterol increased |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126493511 | 12649351 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126493511 | 12649351 | Arthralgia | |
126493511 | 12649351 | Joint lock | |
126493511 | 12649351 | Myalgia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126493511 | 12649351 | 1 | 20160614 | 20160725 | 0 |